Ensartinib (Gevalka)
The treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
In 274 patients with resected ALK-positive stage IB–IIIB NSCLC after adjuvant chemotherapy, 24 months of ensartinib vs placebo raised 24-month disease-free survival in stage II–IIIB disease (86.4% vs 53.5%; HR 0.20). Grade ≥3 adverse events: 35.8% vs 18.2%. RCT · phase 3 · n = 274 · N Engl J Med · 2026
1 trial is being summarised and will appear here shortly.